Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer

Clinical Breast Cancer

Volumn 10, Issue 6, 2010, Pages 465-470

  Irvin Jr , William J ^a,b   Orlowski, Robert Z ^c   Chiu, Wing Keung ^a   Carey, Lisa A ^a,b   Collichio, Frances A ^a,b   Bernard, Philip S ^d   Stijleman, Inge J ^d   Perou, Charles ^a   Ivanova, Anastasia ^a,e   Dees, E Claire ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e IL   (United States)

Author keywords

Dexamethasone; Liver metastases; Ondansetron; Proteasome inhibitor; Pyridoxine; Ranitidine

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; MANNITOL; ONDANSETRON; PYRIDOXINE; RANITIDINE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; DRUG DERIVATIVE; MACROGOL DERIVATIVE; PYRAZINE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ALLERGIC RHINITIS; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BLURRED VISION; BREAST METASTASIS; CANCER PATIENT; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE COURSE; DRUG RESPONSE; DYSPNEA; FATIGUE; FEVER; HAND FOOT SYNDROME; HEADACHE; HOT FLUSH; HUMAN; HYPERPIGMENTATION; HYPERTENSION; HYPOALBUMINEMIA; LYMPHOCYTOPENIA; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROTEINURIA; PRURITUS; RASH; SIDE EFFECT; THROMBOCYTOPENIA; THRUSH; TREATMENT RESPONSE; AGED; BREAST TUMOR; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; FOLLOW UP; MIDDLE AGED; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; POLYETHYLENE GLYCOLS; PYRAZINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 79952277119     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.3816/CBC.2010.n.061     Document Type: Article

References (52)

1. Ciechanover A. Intracellular protein degradation from a vague idea through the lysosome and the ubiquitin-proteasome system and on to human diseases and drug targeting: Nobel Lecture, December 8, 2004. Ann N Y Acad Sci 2007; 1116: 1-28. (Pubitemid 350274349)
2. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-17. (Pubitemid 36741588)
3. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-98. (Pubitemid 41007864)
4. Aghajanian C, Soignet S, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002; 8: 2505-11. (Pubitemid 34856332)
5. Papandreou CN, Daliani DD, Nix D, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004; 22: 2108-21. (Pubitemid 41095144)
6. Kondagunta GV, Drucker B, Schwartz L, et al. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol 2004; 22: 3720-5. (Pubitemid 41095212)
7. Fanucchi MP, Fossella FV, Belt R, et al. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006; 24: 5025-33. (Pubitemid 46631406)
8. Cooper C, Liu GY, Niu YL, et al. Intermittent hypoxia induces proteasomedependent down-regulation of estrogen receptor alpha in human breast carcinoma. Clin Cancer Res 2004; 10: 8720-7. (Pubitemid 40053441)
9. Codony-Servat J, Tapia MA, Bosch M, et al. Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Mol Cancer Ther 2006; 5: 665-75.
10. Cardoso F, Durbecq V, Laes JF, et al. Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner. Mol Cancer Ther 2006; 5: 3042-51. (Pubitemid 46092045)
11. Teicher BA, Ara G, Herbst R, et al. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999; 5: 2638-45. (Pubitemid 29437352)
12. Yang CH, Gonzalez-Angulo AM, Reuben JM, et al. Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann Oncol 2006; 17: 813-7.
13. Engel RH, Brown JA, Von Roenn JH, et al. A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience. Cancer Invest 2007; 25: 733-7. (Pubitemid 350223168)
14. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 2008; 14: 1649-57. (Pubitemid 351469448)
15. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101: 2377-80. (Pubitemid 36302084)
16. Small GW, Somasundaram S, Moore DT, et al. Repression of mitogen-activated protein kinase (MAPK) phosphatase-1 by anthracyclines contributes to their antiapoptotic activation of p44/42-MAPK. J Pharmacol Exp Ther 2003; 307: 861-9. (Pubitemid 37494202)
17. Orlowski RZ, Small GW, Shi YY. Evidence that inhibition of p44/42 mitogenactivated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis. J Biol Chem 2002; 277: 27864-71. (Pubitemid 34966732)
18. Small GW, Shi YY, Edmund NA, et al. Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role. Mol Pharmacol 2004; 66: 1478-90. (Pubitemid 39564774)
19. Shi YY, Small GW, Orlowski RZ. Proteasome inhibitors induce a p38 mitogenactivated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer. Breast Cancer Res Treat 2006; 100: 33-47.
20. Ranson MR, Carmichael J, O'Byrne K, et al. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 1997; 15: 3185-91. (Pubitemid 27419330)
21. Rivera E, Valero V, Esteva FJ, et al. Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer. Cancer Chemother Pharmacol 2002; 49: 299-302. (Pubitemid 34253268)
22. Lyass O, Uziely B, Ben-Yosef R, et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000; 89: 1037-47.
23. Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005; 105: 3058-65.
24. Biehn SE, Moore DT, Voorhees PM, et al. Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin. Ann Hematol 2007; 86: 211-6. (Pubitemid 46195994)
25. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007; 25: 3892-901. (Pubitemid 47477266)
26. Dees EC, O'Neil BH, Lindley CM, et al. A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors. Cancer Chemother Pharmacol 2008; 63: 99-107.
27. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
28. Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27: 1160-7.
29. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10. (Pubitemid 19099520)
30. Cresta S, Sessa C, Catapano CV, et al. Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours. Eur J Cancer 2008; 44: 1829-34.
31. Schmid P, Kuhnhardt D, Kiewe P, et al. A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. Ann Oncol 2008; 19: 871-6. (Pubitemid 351627300)
32. Awada A, Albanell J, Canney PA, et al. Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study. Br J Cancer 2008; 98: 1500-7. (Pubitemid 351652337)
33. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004; 5: 63-9. (Pubitemid 38821193)
34. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-23. (Pubitemid 36842560)
35. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-74. (Pubitemid 32878711)
36. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-74. (Pubitemid 39100473)
37. Hashizume R, Fukuda M, Maeda I, et al. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J Biol Chem 2001; 276: 14537-40.
38. Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003; 95: 1482-5. (Pubitemid 37279334)
39. Meriin AB, Gabai VL, Yaglom J, et al. Proteasome inhibitors activate stress kinases and induce Hsp72. Diverse effects on apoptosis. J Biol Chem 1998; 273: 6373-9. (Pubitemid 28144729)
40. Yang Y, Ikezoe T, Saito T, et al. Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling. Cancer Sci 2004; 95: 176-80. (Pubitemid 38404320)
41. Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003; 101: 1530-4. (Pubitemid 36182530)
42. Liu Y, Gorospe M, Yang C, et al. Role of mitogen-activated protein kinase phosphatase during the cellular response to genotoxic stress. Inhibition of c-Jun N-terminal kinase activity and AP-1-dependent gene activation. J Biol Chem 1995; 270: 8377-80.
43. Franklin CC, Srikanth S, Kraft AS. Conditional expression of mitogen-activated protein kinase phosphatase-1, MKP-1, is cytoprotective against UV-induced apoptosis. Proc Natl Acad Sci USA 1998; 95: 3014-9.
44. Guo YL, Kang B, Williamson JR. Inhibition of the expression of mitogenactivated protein phosphatase-1 potentiates apoptosis induced by tumor necrosis factor-alpha in rat mesangial cells. J Biol Chem 1998; 273: 10362-6. (Pubitemid 28227643)
45. Keyse SM. Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev 2008; 27: 253-61.
46. Liao Q, Guo J, Kleeff J, et al. Down-regulation of the dual-specificity phosphatase MKP-1 suppresses tumorigenicity of pancreatic cancer cells. Gastroenterology 2003; 124: 1830-45. (Pubitemid 36666779)
47. Rojo F, Gonzalez-Navarrete I, Bragado R, et al. Mitogen-activated protein kinase phosphatase-1 in human breast cancer independently predicts prognosis and is repressed by doxorubicin. Clin Cancer Res 2009; 15: 3530-9.
48. Loda M, Capodieci P, Mishra R, et al. Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis. Am J Pathol 1996; 149: 1553-64. (Pubitemid 26363962)
49. Wang HY, Cheng Z, Malbon CC. Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer. Cancer Lett 2003; 191: 229-37. (Pubitemid 36255609)
50. Chauhan D, Catley L, Li G, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005; 8: 407-19. (Pubitemid 41579835)
51. Demo SD, Kirk CJ, Aujay MA, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007; 67: 6383-91. (Pubitemid 47037522)
52. Kuhn DJ, Chen Q, Voorhees PM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007; 110: 3281-90. (Pubitemid 350106321)